Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency
Enrolling by invitation · Phase 3 · NCT02796937
Conditions: Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
At a glance
- Research payments reported, 2025
- $25,097
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 290
About the trial
- Sponsor
- Grifols Therapeutics LLC
- Tested
- Alpha-1 MP (biological)
- Dates
- Started 2016-07; completion 2029-02
- Results posted
- Not yet
This is a 2-year open-label, multicenter extension of the double-blind, placebo-controlled GTi1201 study. The purpose of this study is to obtain an additional 2 years of safety data for intravenously administered Alpha1-MP 60 mg/kg/week in subjects with alpha1-antitrypsin deficiency (AATD).
From ClinicalTrials.gov, last updated 2026-06-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Grifols Therapeutics LLC reported $25,097 in research payments for this study in 2025 (5 payments).
Products named: Prolastin-C Liquid
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rajat Walia, MD Pulmonology · Phoenix, AZ
- Tatsiana Y. Beiko, M.D. Critical Care Medicine · Charleston, SC
- James M. Stocks, MD Pulmonology · Tyler, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Texas Health Science Center at Tyler, TX $12,000
- St Josephs Hospital and Medical Center, AZ $10,007
- Medical University of South Carolina $3,090
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.